SLC5A2 and atrial fibrillation: This class of drugs can also ameliorate outcomes of invasive treatment measures of AF, as a prospective study conducted in China, supported by a meta-analysis, demonstrated that use of SGLT-2 inhibitors led to reduced risk of AF recurrence in patients with diabetes following ablation [114].